Affiliation:
1. Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill , Chapel Hill, NC , USA
2. UNC Lineberger Comprehensive Cancer Center , Chapel Hill, NC , USA
Abstract
Abstract
Objectives
Neoadjuvant chemotherapy (NAC) confers a survival advantage for muscle-invasive bladder cancer and is now recommended for chemotherapy-eligible patients. NAC may result in absent gross tumor, and current cystectomy gross examination protocols do not specify approach for these cases.
Methods
We included cystectomies performed from 2010 to 2018, capturing a period pre- and post-NAC recommendations. Gross descriptions were reviewed and slides of patients who received NAC were evaluated for microscopic tumor, number of blocks with tumor, and location of those blocks.
Results
We identified 239 radical cystectomies for bladder cancer (147 NAC, 92 non-NAC). Gross lesions were not identified for 91 cases. NAC cases had more total blocks submitted (mean, 17.5) compared with non-NAC cases (mean, 16.6). More NAC cases had additional blocks submitted (20 cases) compared with non-NAC cases (2), which were more frequently additional random sections. Of 108 NAC cases with residual carcinoma, only 2 (1.9%) were upstaged on additional random sections.
Conclusions
At our institution, NAC and non-NAC cases are grossed with similar numbers of initial blocks; however, NAC cases are more likely to submit additional sections of gross lesions and random bladder without significant changes in stage. Our data suggest current gross examination protocols are sufficient for NAC cystectomies.
Publisher
Oxford University Press (OUP)
Reference26 articles.
1. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer;Grossman;N Engl J Med.,2003
2. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 Trial;Medical Research Council Advanced Bladder Cancer Working Party, European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, et al;J Clin Oncol.,2011
3. Increasing utilization of neoadjuvant chemotherapy for muscle-invasive bladder cancer in the United States;Keegan;Curr Urol Rep.,2014
4. Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology;Flaig;J Natl Compr Canc Netw.,2020